Kinetics of integrin expression in the mouse model of proliferative retinopathy and success of secondary intervention with cyclic RGD peptides

被引:35
作者
Chavakis, E
Riecke, B
Lin, J
Linn, T
Bretzel, RG
Preissner, KT
Brownlee, M
Hammes, HP [1 ]
机构
[1] Univ Heidelberg, Fac Med, Med Clin 5, D-6800 Mannheim, Germany
[2] Albert Einstein Coll Med, Diabet Res Dept Pathol, New York, NY USA
[3] Albert Einstein Coll Med, Diabet Res Dept Med, New York, NY USA
[4] Univ Giessen, Inst Biochem, Giessen, Germany
[5] Univ Giessen, Dept Med 3, Giessen, Germany
关键词
endothelial proliferation; retinopathy; alpha(v)-type integrins; microvessels; vascular endothelial growth factor; basic fibroblast growth factor;
D O I
10.1007/s00125-001-0727-z
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims/hypothesis. Vitronectin-receptor-type integrins (a(nu)beta(3) and a(nu)beta(5)) are thought to be involved in the selective ablation of tumorigenic and other pathologic angiogenesis. Specifically, it has been shown that ligation inhibition of the a(v)-type integrins with cyclic penta-peptid peptide inhibits proliferative retinopathy by almost 80 % in a hypoxia-induced mouse model. Methods. On the basis of growth factor and integrin expression dynamics in this model, secondary intervention approaches with cyclic RGDfV peptide were investigated. Results. a(v)-integrin expression started immediately after induction of hypoxia (at postnatal day 12, p 12) and persisted only during the initial period of neovascularization (until day p14). Vascular endothelial growth factor (VEGF) expression started at high values immediately after return of the mice into room air, and dropped rapidly to low values beyond day 13. In contrast, basic fibroblast growth factor (bFGF) was predominantly expressed during the phase of maximum angiogenesis which was noted between day p17 and 19. Based on these findings, cyclic penta peptide was administered subcutaneously at varying doses (2-20 mug/kg/day) for 5 days beginning either at day p14 (early intervention) or at day p17 (late intervention). Early secondary intervention showed a dose-dependent reduction of new vessels with maximum inhibition of 57% (control 68.08 +/- 3.21 nuclei/section compared with RGDfV-treated 29.35 +/- 2.39 nuclei/section; p < 0.0001), whereas late secondary intervention had no effect. Conclusion/hypothesis. These data indicate that angiogenesis-related a(v)-integrin expression is VEGF-rather than bFGF-dependent, and the efficacy of cyclic penta-peptid (RGDfV)-treatment in proliferative retinopathy is only effective as long as the a(v)-integrin target is prominently expressed.
引用
收藏
页码:262 / 267
页数:6
相关论文
共 31 条
[1]   ARG-GLY-ASP CONSTRAINED WITHIN CYCLIC PENTAPEPTIDES - STRONG AND SELECTIVE INHIBITORS OF CELL-ADHESION TO VITRONECTIN AND LAMININ FRAGMENT-P1 [J].
AUMAILLEY, M ;
GURRATH, M ;
MULLER, G ;
CALVETE, J ;
TIMPL, R ;
KESSLER, H .
FEBS LETTERS, 1991, 291 (01) :50-54
[2]   Extensive vasculogenesis, angiogenesis, and organogenesis precede lethality in mice lacking all αv integrins [J].
Bader, BL ;
Rayburn, H ;
Crowley, D ;
Hynes, RO .
CELL, 1998, 95 (04) :507-519
[3]   COORDINATE EXPRESSION OF VASCULAR ENDOTHELIAL GROWTH-FACTOR RECEPTOR-1 (FLT-1) AND ITS LIGAND SUGGESTS A PARACRINE REGULATION OF MURINE VASCULAR DEVELOPMENT [J].
BREIER, G ;
CLAUSS, M ;
RISAU, W .
DEVELOPMENTAL DYNAMICS, 1995, 204 (03) :228-239
[4]   REQUIREMENT OF VASCULAR INTEGRIN ALPHA(V)BETA(3) FOR ANGIOGENESIS [J].
BROOKS, PC ;
CLARK, RAF ;
CHERESH, DA .
SCIENCE, 1994, 264 (5158) :569-571
[5]   INTEGRIN ALPHA(V)BETA(3) ANTAGONISTS PROMOTE TUMOR-REGRESSION BY INDUCING APOPTOSIS OF ANGIOGENIC BLOOD-VESSELS [J].
BROOKS, PC ;
MONTGOMERY, AMP ;
ROSENFELD, M ;
REISFELD, RA ;
HU, TH ;
KLIER, G ;
CHERESH, DA .
CELL, 1994, 79 (07) :1157-1164
[6]  
CASAROLI MRP, 1995, EXP EYE RES, V60, P5
[7]   THE FMS-LIKE TYROSINE KINASE, A RECEPTOR FOR VASCULAR ENDOTHELIAL GROWTH-FACTOR [J].
DEVRIES, C ;
ESCOBEDO, JA ;
UENO, H ;
HOUCK, K ;
FERRARA, N ;
WILLIAMS, LT .
SCIENCE, 1992, 255 (5047) :989-991
[8]   The role of αv integrins during angiogenesis:: insights into potential mechanisms of action and clinical development [J].
Eliceiri, BP ;
Cheresh, DA .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 103 (09) :1227-1230
[9]   ANGIOGENESIS IN CANCER, VASCULAR, RHEUMATOID AND OTHER DISEASE [J].
FOLKMAN, J .
NATURE MEDICINE, 1995, 1 (01) :27-31
[10]   DEFINITION OF 2 ANGIOGENIC PATHWAYS BY DISTINCT ALPHA(V) INTEGRINS [J].
FRIEDLANDER, M ;
BROOKS, PC ;
SHAFFER, RW ;
KINCAID, CM ;
VARNER, JA ;
CHERESH, DA .
SCIENCE, 1995, 270 (5241) :1500-1502